Rasagiliini

Rasagiliini, also known as Rasagiline, is a medication primarily used in the treatment of Parkinson's disease. It belongs to the class of drugs known as monoamine oxidase B (MAO-B) inhibitors. Rasagiliini works by increasing the levels of dopamine, a neurotransmitter that is depleted in Parkinson's disease, thereby improving motor symptoms such as tremors, rigidity, and bradykinesia.

The drug is typically taken orally, usually once or twice daily, and is available in various strengths. Rasagiliini is often prescribed as an adjunct to levodopa, a commonly used medication for Parkinson's disease, to help manage the wearing-off phenomenon, where symptoms worsen as the levodopa wears off.

Common side effects of rasagiliini include nausea, dizziness, and insomnia. Serious side effects are rare but can include serotonin syndrome, a potentially life-threatening condition that occurs when there is an excess of serotonin in the body. It is important to inform healthcare providers about all medications being taken, as rasagiliini can interact with certain drugs, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants.

Rasagiliini was approved for medical use in the United States in 2003. It is marketed under the brand name Azilect and is available in generic form. The drug is generally well-tolerated, but individual responses may vary, and it is essential to follow the advice of a healthcare professional regarding its use.